Salarius Pharmaceuticals (NASDAQ:SLRX) Announces Earnings Results

Salarius Pharmaceuticals (NASDAQ:SLRX) issued its quarterly earnings data on Friday. The company reported ($0.66) earnings per share (EPS) for the quarter, Zacks reports.

Salarius Pharmaceuticals Stock Performance

Salarius Pharmaceuticals stock traded up $0.06 during mid-day trading on Friday, reaching $0.95. 20,802 shares of the company were exchanged, compared to its average volume of 1,225,875. The firm’s 50-day simple moving average is $1.73 and its two-hundred day simple moving average is $1.61. Salarius Pharmaceuticals has a twelve month low of $0.83 and a twelve month high of $7.20. The firm has a market cap of $1.65 million, a PE ratio of -0.12 and a beta of 0.59.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.